NIH, National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) NIH - National Institutes of Health National Cancer Institute DCTD - Division of Cancer Treatment and Diagnosis

Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry.

Author(s): Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC, Tempst P

Publication: Anal Chem, 2004, Vol. 76, Page 1560-70

PubMed ID: 15018552 PubMed Review Paper? No

Purpose of Paper

The purpose of this paper was to determine the effects of specimen preparation method and MALDI-TOF protocols on serum peptide profiles.

Conclusion of Paper

Using magnetic beads derivatized with a carbon chain length of 8 (C8), 50 ug beads/uL serum, elution with 50% acetonitrile (MeCN) at 1 uL MeCN per 500 ug beads, alpha-cyano-4-hydroxy-trans-cinnamic acid (HCCA) as the matrix, 40% MeCN/50% methanol/10% water as the solvent, and 20-30 higher power laser shots prior to data acquisition in the linear mode resulted in a high number of peaks. This number of peaks could be slightly increased by applying the serum to a strong cation exchange column (SCAX) and eluting at increasing concentrations of sodium chloride before application to C8 beads and by a two-step MeCN elution. Similar spectra were observed when specimen handling was manual or automated. Use of the protocol outlined above allowed for identification of peptides differentially expressed between healthy controls and glioblastoma patients.

Studies

  1. Study Purpose

    The purpose of this study was to determine the effects of specimen preparation method and MALDI-TOF protocols on serum peptide profiles. Serum was stored at -80 degrees C until analysis.

    Summary of Findings:

    Using only magnetic beads derivatized with C8 resulted in the largest number of MALDI-TOF peaks both in the 0.8-4Kda and 4-15 Kda range, and the authors report using beads with a porous surface improved binding capacity. The maximum number of peaks attainable was similar for all serum amounts, and a ratio of 50 ug beads/uL serum resulted in the highest number of MALDI-TOF peaks. More peaks resulted from elution with 50% MeCN at 1 uL MeCN per 500 ug beads than 20% or 70% MeCN, methanol, 2-propanol, or ethanol of from more or less MeCN, but two-step elution (20% MeCN, then 70% MeCN) increased the number of peaks by 8%. Pretreatment of serum with urea, urea/dithiothreitol (DTT), ethanol precipitation, cibachron blue, or ultrafiltration, with or without urea, decreased the number of MALDI-TOF peaks, and prewashing the serum tubes with n-octylglucoside did not increase the number of peptide peaks. Applying the serum to SCAX and eluting with increasing concentrations of sodium chloride applied to C8 beads increased the number of peaks by 30. Using HCCA as the MALDI-TOF matrix and 40% MeCN/50% methanol/10% water as the solvent resulted in more peaks than using 2,5-dihydroxybenzoic acid (DHB) or sinapic acid as the matrix and other concentrations of MeCN, methanol, 2-propanol, water and trifluoroacetic acid (TFA) as the solvent. Using 20-30 higher power laser shots prior to 100 laser shots at lower power increased the number of peaks compared to acquiring data with 100 lower power laser shots. Using the linear mode during acquisition rather than reflectron increased the number of peaks by a factor of 4. Similar spectra were observed when specimen handling was manual or automated. Use of the automated protocol allowed for identification of peptides differentially expressed between healthy controls and glioblastoma patients.

    Biospecimens
    Preservative Types
    • Frozen
    Diagnoses:
    • Normal
    • Neoplastic - Sarcoma
    Platform:
    AnalyteTechnology Platform
    Peptide MALDI-TOF MS
    Protein MALDI-TOF MS
    Pre-analytical Factors:
    ClassificationPre-analytical FactorValue(s)
    Preaquisition Diagnosis/ patient condition Normal volunteer
    Glioblastoma
    Biospecimen Aliquots and Components Filtration Centricon 30 ultrafiltration after incubation with urea
    No filtration
    Analyte Extraction and Purification Analyte purification Methanol
    2-propanol
    Ethanol
    Acetonitrile
    20%
    50%
    70%
    1-step
    2-step
    C1 magnetic beads
    C2 magnetic beads
    C3 magnetic beads
    C8 magnetic beads
    C18 magnetic beads
    C3 and C8 magnetic beads
    C8 and C18 magnetic beads
    C1 or C2 and then C8 magnetic beads
    Various concetrations beads
    Automated preparation
    Biospecimen Acquisition Type of collection container/solution Untreated serum tube
    Serum tube treated with n-octylglucoside
    MALDI-TOF MS Specific Template modification Urea
    Urea/DTT
    Ethanol precipitation
    Ultrafiltration
    Cibachron blue
    None
    MALDI-TOF MS Specific Reaction solution Various concentrations of MeCN, methanol, 2-propanol, water and TFA
    MALDI-TOF MS Specific Detection method 20-30 higher power laser shots prior 100 standard power shots
    Standard laser power for all shots
    MALDI-TOF MS Specific Technology platform Linear mode
    Reflectron
    Biospecimen Aliquots and Components Aliquot size/volume 5 ul serum
    20 ul serum
    50 ul serum
    100 ul serum

You Recently Viewed  

News and Announcements

  • April 24, 2024: Biobanking for Precision Medicine Seminar

  • Most Popular SOPs in March 2024

  • New SOPs Available

  • More...